NLRP3 might be the “golden” therapeutic target of inflammatory morbidities, including neurodegenerative disorders (e.g., Alzheimer’s disease [AD]) [27,28,29]. The gene discussed is NLRP3; the disease is early-onset autosomal dominant Alzheimer disease.